Search results for: David T. Rubin

Items from 1 to 20 out of 198 results

article

Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial

Yaara Zisman‐Ilani, Kimberly D. Thompson, Lori S. Siegel, Todd Mackenzie, more

Alimentary Pharmacology & Therapeutics > 57 > 2 > 205 - 214

Background Crohn's disease requires effective patient‐clinician communication for successful illness and medication management. Shared decision making (SDM) has been suggested to improve communication around early intensive therapy. However, effective evidence‐based SDM interventions for Crohn's disease are lacking, and the impact of SDM on Crohn's disease decision making and choice of therapy is...

article

Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management

Sasha R. Fehily, Aysha H. Al‐Ani, Jonathan Abdelmalak, Clarissa Rentch, more

Alimentary Pharmacology & Therapeutics > 56 > 1 > 6 - 27

Background One quarter of the world's population has latent tuberculosis infection (LTBI). Systemic immunosuppression is a risk factor for LTBI reactivation and the development of active tuberculosis. Such reactivation carries a risk of significant morbidity and mortality. Despite the increasing global incidence of inflammatory bowel disease (IBD) and the use of immune‐based therapies, current guidelines...

article

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis

David T. Rubin, Irene Modesto, Séverine Vermeire, Silvio Danese, more

Alimentary Pharmacology & Therapeutics > 55 > 3 > 302 - 310

Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Post‐marketing surveillance (PMS) is an important part of monitoring adverse events (AEs). Aims To report an analysis of PMS case safety reports for tofacitinib in patients with UC Methods Worldwide tofacitinib PMS reports received in the Pfizer safety database from 30 May 2018 (first regulatory...

article

Predictability of simple endoscopic score for Crohn's disease for postoperative outcomes in Crohn's disease

Shintaro Akiyama, Akihiro Yamada, Jacob E Ollech, Yuga Komaki, more

Journal of Gastroenterology and Hepatology > 36 > 10 > 2785 - 2793

Background and Aim Approximately half of patients with Crohn's disease (CD) who have surgery will experience clinical recurrence within 10 years of their surgery. This study aimed to assess the postoperative outcomes according to disease location and validated the simple endoscopic score for CD (SES‐CD) to predict disease‐related outcomes. Methods We retrospectively assessed medical records of...

article

Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission

Neeraj Narula, Achuthan Aruljothy, Abdul‐Aziz Alshahrani, Ma’ayan Fadida, more

Alimentary Pharmacology & Therapeutics > 52 > 11-12 > 1676 - 1682

Background Histologic remission in ulcerative colitis (UC) patients may be associated with positive outcomes. It is unclear whether UC patients in endoscopic remission obtain additional benefit from achieving histologic remission. Aim To evaluate the relationship between time to relapse and histological activity among UC patients in endoscopic remission. Methods In this retrospective study using...

article

Long‐term safety of vedolizumab for inflammatory bowel disease

Edward V. Loftus, Brian G. Feagan, Remo Panaccione, Jean‐Frédéric Colombel, more

Alimentary Pharmacology & Therapeutics > 52 > 8 > 1353 - 1365

Background Vedolizumab, a gut‐selective α₄β₇ integrin antibody, is approved for moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). Aim To report the final results from the vedolizumab GEMINI long‐term safety (LTS) study. Methods The phase 3, open‐label GEMINI LTS study (initiated May 2009) enrolled patients with UC or CD from four prior clinical trials and vedolizumab‐naïve...

article

Practical advice for management of inflammatory bowel diseases patients during the COVID‐19 pandemic: World Endoscopy Organization Statement

Helmut Neumann, Fabian Emura, Bernd Bokemeyer, Nalini Guda, more

Digestive Endoscopy > 32 > 5 > 658 - 662

COVID‐19 is rapidly spreading worldwide and specific literature how to deal with inflammatory bowel diseases (IBD) patients is limited so far. Here, the World Endoscopy Organisation is providing practical advice for the management of IBD patients during the pandemic covering the diagnostic and therapeutic spectrum.

article

Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient

Aysha H. Al‐Ani, Ralley E. Prentice, Clarissa A. Rentsch, Doug Johnson, more

Alimentary Pharmacology & Therapeutics > 52 > 1 > 54 - 72

Background The current COVID‐19 pandemic, caused by SARS‐CoV‐2, has emerged as a public health emergency. All nations are seriously challenged as the virus spreads rapidly across the globe with no regard for borders. The primary management of IBD involves treating uncontrolled inflammation with most patients requiring immune‐based therapies. However, these therapies may weaken the immune system and...

article

Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease

Jingzhou Wang, Joshua Prenner, Wenfei Wang, Atsushi Sakuraba, more

Alimentary Pharmacology & Therapeutics > 51 > 12 > 1365 - 1372

Background Insufficient data exist for peristomal pyoderma gangrenosum (PPG), which primarily affects patients with inflammatory bowel disease (IBD). Aims To evaluate the risk factors and treatment response of PPG in IBD patients in a real‐life cohort. Methods Cases of PPG were identified retrospectively using ICD‐9/10 codes in patients with IBD who had an ostomy at a tertiary care centre. Disease‐specific...

article

Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid‐refractory ulcerative colitis

Jacob E. Ollech, Sujaata Dwadasi, Victoria Rai, Noam Peleg, more

Alimentary Pharmacology & Therapeutics > 51 > 6 > 637 - 643

Background Following induction therapy with a calcineurin inhibitor (CNI) in severe ulcerative colitis, transitioning to vedolizumab as maintenance therapy could be an option. Aim To report on the largest cohort of patients successfully induced with CNIs who were transitioned to vedolizumab maintenance therapy. Methods This is a retrospective observational study of adult patients with severe...

article

Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist‐maintained clinical remission

Yunwei Wang, Jennifer Wang, Joel Pekow, Sushila Dalal, more

Journal of Gastroenterology and Hepatology > 34 > 12 > 2090 - 2095

Background and Aim Vedolizumab (VDZ) has been used in inflammatory bowel disease (IBD) patients who failed anti‐tumor necrosis factor (TNF) therapy. This study was to examine long‐term outcome of IBD patients switching to VDZ from anti‐TNF agents for reasons other than failure of therapy. Methods Inflammatory bowel disease patients at the University of Chicago IBD center who were in clinical remission...

article

Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis

Jacob E. Ollech, David T. Rubin, Laura Glick, Roni Weisshof, more

Digestive Diseases and Sciences > 2019 > 64 > 12 > 3596-3601

Background Chronic antibiotic-refractory pouchitis (CARP) occurs in up to 15% of patients with ulcerative colitis (UC) following proctocolectomy with ileal pouch–anal anastomosis (IPAA). Aim To investigate the effectiveness of ustekinumab in the treatment of CARP. Methods This was a retrospective single-center study of UC patients with an IPAA, who subsequently developed CARP and received ustekinumab...

article

Real-World Experience with Tofacitinib in IBD at a Tertiary Center

Roni Weisshof, Maya Aharoni Golan, Philip H. Sossenheimer, Katia El Jurdi, more

Digestive Diseases and Sciences > 2019 > 64 > 7 > 1945-1951

Background and Aims Many inflammatory bowel disease (IBD) patients do not respond to medical therapy. Tofacitinib is a first-in-class, partially selective inhibitor of Janus kinase, recently approved for treating patients with ulcerative colitis (UC). We describe our experience with the use of tofacitinib for treatment of patients with moderate-to-severe IBD. Methods This is a retrospective, observational...

article

Emerging Therapies for Inflammatory Bowel Disease

Roni Weisshof, Katia El Jurdi, Nada Zmeter, David T. Rubin

Advances in Therapy > 2018 > 35 > 11 > 1746-1762

Inflammatory bowel disease (IBD) is a chronic heterogeneous group of diseases that has undergone major advances in the understanding of its etiology and pathogenesis in recent years. The development of biologics had resulted in better overall management of the disease, including lower rates of surgery and better long-term clinical and patient-reported outcomes. Treatment modalities have either been...

article

A comparison of the risk of postoperative recurrence between African‐American and Caucasian patients with Crohn's disease

Adjoa Anyane‐Yeboa, Akihiro Yamada, Haider Haider, Yunwei Wang, more

Alimentary Pharmacology & Therapeutics > 48 > 9 > 933 - 940

Background Many patients with Crohn's disease will develop complications that require surgery. Recurrence after surgery is common. Aim To assess racial differences in postoperative recurrence between African‐Americans and Caucasians. Methods Medical records of Crohn's disease patients who underwent surgery (ileal, colonic, or ileocolonic resection) between June 2014 and June 2016 were reviewed...

article

Correction to: Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study

Dejan Micic, Andres Yarur, Alex Gonsalves, Vijaya L. Rao, more

Digestive Diseases and Sciences > 2018 > 63 > 10 > 2815-2815

The original version of the article unfortunately contained an error in a percentage value in Results section of Abstract.

article

Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn’s Disease

Silvio Danese, Stefanos Bonovas, Anthony Lopez, Gionata Fiorino, more

Gastroenterology > 2018 > 155 > 1 > 76-87

Intestinal fibrosis is a challenge to management of patients with Crohn’s disease (CD); there is an urgent need to expedite development of antifibrosis drugs for this disease. The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) aimed to identify a set of endpoints that can be used to determine efficacy of antifibrosis agents tested in clinical trials of patients with...

article

Su1805 - Fecal Calprotectin is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location

Anthony Buisson, Wing Yan Mak, Michael J. Andersen, Donald Lei, more

Gastroenterology > 2018 > 154 > 6(S1) > S-590-S-591

article

Su1810 - Faecal Calprotectin is a Very Reliable Tool to Predict and Monitor the Risk of Relapse after Therapeutic De-Escalation in Patients with Inflammatory Bowel Disease

Anthony Buisson, Wing Yan Mak, Michael J. Andersen, Donald Lei, more

Gastroenterology > 2018 > 154 > 6(S1) > S-593

article

94 - Daily Aspirin Use does not Impact Clinical Outcomes in Patients with Inflammatory Bowel Disease

Parita Patel, Guimin Gao, George E. Gulotta, David T. Rubin, more

Gastroenterology > 2018 > 154 > 6(S1) > S-28

Publication date

Last 3 years (3)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

Publication type

article (196)
book (2)

INFONA - science communication portal

Search results for: David T. Rubin

Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial

Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis

Predictability of simple endoscopic score for Crohn's disease for postoperative outcomes in Crohn's disease

Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission

Long‐term safety of vedolizumab for inflammatory bowel disease

Practical advice for management of inflammatory bowel diseases patients during the COVID‐19 pandemic: World Endoscopy Organization Statement

Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient

Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease

Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid‐refractory ulcerative colitis

Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist‐maintained clinical remission

Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis

Real-World Experience with Tofacitinib in IBD at a Tertiary Center

Emerging Therapies for Inflammatory Bowel Disease

A comparison of the risk of postoperative recurrence between African‐American and Caucasian patients with Crohn's disease

Correction to: Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study

Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn’s Disease

Su1805 - Fecal Calprotectin is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location

Su1810 - Faecal Calprotectin is a Very Reliable Tool to Predict and Monitor the Risk of Relapse after Therapeutic De-Escalation in Patients with Inflammatory Bowel Disease

94 - Daily Aspirin Use does not Impact Clinical Outcomes in Patients with Inflammatory Bowel Disease

Filter options

Publication date

Publication type

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: David T. Rubin

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Publication type

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options